See more : Grupo Famsa, S.A.B. de C.V. (GFAMSAA.MX) Income Statement Analysis – Financial Results
Complete financial analysis of Carisma Therapeutics, Inc. (CARM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Carisma Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Dongbu Corporation (005965.KS) Income Statement Analysis – Financial Results
- Top Ships Inc. (TOPS) Income Statement Analysis – Financial Results
- Al Taiseer Group Talco Industrial Co. (4143.SR) Income Statement Analysis – Financial Results
- Glenfarne Merger Corp. (GGMC) Income Statement Analysis – Financial Results
- Traccom Inc. (TRCC) Income Statement Analysis – Financial Results
Carisma Therapeutics, Inc. (CARM)
About Carisma Therapeutics, Inc.
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14.92M | 9.83M | 26.54M | 11.24M | 0.00 | 0.00 | 425.00K | 29.98M | 990.00K | 2.24M | 1.33M | 0.00 | 0.00 |
| Cost of Revenue | 74.13M | 6.09M | 85.00K | 0.00 | 219.00K | 208.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -59.21M | 3.74M | 26.46M | 11.24M | -219.00K | -208.00K | 425.00K | 29.98M | 990.00K | 2.24M | 1.33M | 0.00 | 0.00 |
| Gross Profit Ratio | -396.85% | 38.07% | 99.68% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 74.13M | 56.62M | 34.39M | 23.29M | 24.44M | 13.87M | 12.23M | 12.20M | 25.97M | 26.70M | 13.79M | 15.26M | 9.41M |
| General & Administrative | 29.53M | 9.38M | 6.41M | 5.09M | 12.21M | 11.62M | 8.07M | 14.74M | 9.85M | 8.47M | 4.02M | 4.21M | 3.27M |
| Selling & Marketing | 0.00 | 30.41M | 0.00 | 0.00 | 0.00 | 0.00 | -170.00K | -3.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 29.53M | 3.29M | 6.41M | 5.09M | 12.21M | 11.62M | 7.90M | 11.44M | 9.85M | 8.47M | 4.02M | 4.21M | 3.27M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 103.65M | 59.91M | 40.79M | 28.38M | 36.65M | 25.49M | 20.13M | 23.64M | 35.82M | 35.17M | 17.81M | 19.48M | 12.68M |
| Cost & Expenses | 103.65M | 66.00M | 40.79M | 28.38M | 36.87M | 25.70M | 20.41M | 23.82M | 36.19M | 35.17M | 17.81M | 19.48M | 12.68M |
| Interest Income | 1.94M | 1.85M | 10.00K | 29.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 3.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 247.00K | 1.40M | 376.00K | 1.40M | 168.00K | 151.00K |
| Depreciation & Amortization | 2.84M | 6.09M | 85.00K | 122.00K | 219.00K | 208.00K | 285.00K | 178.00K | 366.00K | 410.00K | 438.00K | 448.00K | 364.00K |
| EBITDA | -85.89M | -51.99M | -40.11M | -27.93M | -107.28M | -33.49M | -28.74M | 2.32M | -31.69M | -33.37M | -17.18M | -19.04M | -12.31M |
| EBITDA Ratio | -575.74% | -509.17% | -151.12% | -248.58% | 0.00% | 0.00% | -4,635.29% | 21.16% | -3,518.18% | -1,487.74% | -1,213.42% | 0.00% | 0.00% |
| Operating Income | -88.73M | -56.16M | -40.79M | -28.38M | -36.87M | -25.70M | -19.99M | 6.17M | -35.20M | -33.78M | -16.63M | -19.49M | -12.68M |
| Operating Income Ratio | -594.75% | -571.10% | -153.68% | -252.56% | 0.00% | 0.00% | -4,702.35% | 20.57% | -3,555.15% | -1,506.02% | -1,246.25% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.85M | -5.06M | 10.00K | 29.00K | -70.63M | -7.99M | -9.04M | -4.27M | 1.74M | -1.23M | -1.40M | -168.00K | -151.00K |
| Income Before Tax | -86.88M | -61.23M | -40.78M | -28.35M | -107.50M | -33.69M | -29.03M | 1.90M | -33.45M | -34.16M | -18.03M | -19.66M | -12.83M |
| Income Before Tax Ratio | -582.34% | -622.60% | -153.65% | -252.31% | 0.00% | 0.00% | -6,830.35% | 6.32% | -3,378.99% | -1,522.78% | -1,351.20% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -3.88M | -10.00K | -29.00K | 0.00 | 46.86K | 0.00 | 5.00K | 1.40M | 376.00K | 1.40M | 168.00K | 151.00K |
| Net Income | -86.88M | -61.23M | -40.77M | -28.32M | -107.50M | -33.69M | -29.03M | 1.89M | -33.45M | -34.53M | -19.43M | -19.83M | -12.98M |
| Net Income Ratio | -582.34% | -622.60% | -153.61% | -252.05% | 0.00% | 0.00% | -6,830.35% | 6.31% | -3,378.99% | -1,539.55% | -1,456.15% | 0.00% | 0.00% |
| EPS | -2.59 | -575.42 | -4.47 | -4.79 | -23.64 | -10.91 | -22.24 | 1.79 | -35.23 | -47.16 | -45.50 | -55.70 | -30.39 |
| EPS Diluted | -2.59 | -575.42 | -4.47 | -4.79 | -23.64 | -10.91 | -22.24 | 1.74 | -35.23 | -47.16 | -45.50 | -55.70 | -30.39 |
| Weighted Avg Shares Out | 33.52M | 106.40K | 9.12M | 5.91M | 4.55M | 3.09M | 1.31M | 1.05M | 949.65K | 732.20K | 426.95K | 355.90K | 426.95K |
| Weighted Avg Shares Out (Dil) | 33.52M | 106.40K | 9.12M | 5.91M | 4.55M | 3.09M | 1.31M | 1.09M | 949.65K | 732.20K | 426.95K | 355.90K | 426.95K |
10 Top Penny Stocks To Buy For Under $1 May 2022 Edition
Top penny stocks under $1 to watch in May. The post 10 Top Penny Stocks To Buy For Under $1 May 2022 Edition appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
3 Penny Stocks That Pushed Up During Trading Today
Why these three penny stocks shot up during trading on May 5th The post 3 Penny Stocks That Pushed Up During Trading Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Hot Penny Stocks To Buy For Under $1 This Week
Hot penny stocks under $1 to watch this week. The post Hot Penny Stocks To Buy For Under $1 This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Best Penny Stocks To Buy Now? 5 Stocks Under $1 To Watch In April
Penny stocks under $1 to watch right now. The post Best Penny Stocks To Buy Now?
6 of the Best Penny Stocks Under $1 to Buy Now for 2022
These penny stocks trading for under $1 per share all have strong chances of delivering stunning returns in the coming year. The post 6 of the Best Penny Stocks Under $1 to Buy Now for 2022 appeared first on InvestorPlace.
4 Penny Stocks To Buy For Under $1 On Webull
Cheap penny stocks to watch this week. The post 4 Penny Stocks To Buy For Under $1 On Webull appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Sesen Bio Stock (SESN): Why The Price Substantially Fell Today
The stock price of Sesen Bio Inc (NASDAQ: SESN) fell by 17.58% today. This is why it happened.
Why Sesen Bio Stock Got Slammed Today
The company's hopeful words about its pipeline drug fell on deaf ears.
Sesen Bio To Conduct Additional Trial For Potential Resubmission Of Vicineum In Bladder Cancer
Sesen Bio Inc (NASDAQ: SESN) has outlined its anticipated regulatory path forward for Vicineum for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) following its Clinical Type A meeting with the FDA. Following the meeting, the Company has agreed to conduct a randomized clinical trial...
7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts
These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months. The post 7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts appeared first on InvestorPlace.
Source: https://incomestatements.info
Category: Stock Reports